A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma
| Autor: | Dung T. Le, Daniel A. Laheru, David Cosgrove, Lei Zheng, Katharine Kinsman, Edna I. Flores, Ki Y. Chung, Ana De Jesus-Acosta, Luis A. Diaz, Amanda L. Blackford, Ross C. Donehower, George R. Oliver, Lalan S. Wilfong |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Neutropenia Survival FOLFIRINOX Docetaxel Kaplan-Meier Estimate Adenocarcinoma Toxicology Deoxycytidine Capecitabine Pancreatic cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Chemotherapy Pharmacology (medical) Neoplasm Metastasis Aged Retrospective Studies Pharmacology Aged 80 and over Toxicity business.industry Alanine Transaminase Metastatic Pancreatic Adenocarcinoma Middle Aged medicine.disease Gemcitabine Hospitalization Pancreatic Neoplasms Regimen Treatment Outcome Female Taxoids Original Article Fluorouracil business medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology |
| ISSN: | 1432-0843 |
| Popis: | Purpose Studies treating adenocarcinoma of the pancreas with gemcitabine alone or in combination with a doublet have demonstrated modest improvements in survival. Recent reports have suggested that using the triple-drug regimen FOLFIRINOX can substantially extend survival in patients with metastatic disease. We were interested in determining the clinical benefit of another three-drug regimen of gemcitabine, docetaxel and capecitabine (GTX) in patients with advanced pancreatic adenocarcinoma. Patients and methods The cases of 154 patients, who received treatment with GTX chemotherapy with histologically confirmed locally advanced or metastatic pancreatic adenocarcinoma, were retrospectively reviewed. All demographic and clinical data were captured including prior therapy, adverse events, treatment response and survival. Results One hundred and seventeen metastatic and 37 locally advanced cases of adenocarcinoma of the pancreas were reviewed. Partial responses were noted in 11% of cases, and stable disease was observed in 62% of patients. Responses significantly correlated with toxicity (neutropenia, ALT elevation and hospitalizations). Grade 3 or greater hematologic and non-hematologic toxicities were noted in 41% and 9% of cases, respectively. Overall median survival was 11.6 months. Chemotherapy naïve patients with metastatic and locally advanced disease achieved a median survival of 11.3 and 25.0 months, respectively. Conclusions We observe a substantial survival benefit with GTX chemotherapy in our cohort of patients with advanced pancreatic cancer. These findings warrant further investigation of this combination in this patient population. Electronic supplementary material The online version of this article (doi:10.1007/s00280-011-1704-y) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink